Express Pharma

Cipla launches Spirofy, strengthens its lung leadership position by facilitating early diagnosis for COPD1

Spirofy is India's first pneumotach-based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD) and asthma

0 429

Cipla today announced the launch of Spirofy, India’s first pneumotach-based portable, wireless Spirometer, on World COPD Day. With this launch, the company intends to revolutionise Obstructive Airway Disease (OAD) diagnosis, in line with its ambition to strengthen its position as the lung leader in India, the company notified via a statement.

The statement further said that Cipla’s Spirofy is a result of five years of meticulous in-house research by the Integrated Product Development (IPD) team, and it aims to transform Obstructive Airway Disease (OAD) diagnosis in India. This advanced device ensures high result accuracy and individual patient safety using bacterial viral filters. Spirofy is entirely wireless with good battery backup, making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians’ flexibility and ease of use. The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a PDF version can be shared on the phone. Cipla will undertake training of physicians in the interpretation of spirometry results.

Commenting on the launch, Umang Vohra, MD and Global CEO, Cipla, said, “Cipla has been steadfastly focussed on addressing the world’s growing respiratory disease burden, and with this launch, we see ourselves steadily advancing to combat chronic respiratory ailments like COPD. The Spirofy launch aims to help doctors across the country to improve lives of patients through accurate and affordable diagnosis.”

- Advertisement -